Microvascular Dysfunction in Symptomatic Patients with Intermediate Coronary Lesions Prognostic impact according to different patterns

Coronary microvascular dysfunction (CMD) is emerging as an important cause of myocardial ischemia, and its role in the pathogenesis of cardiovascular disease—including angina patients with nonobstructive coronary lesions—is well known. Currently, there are several definitions of CMD and several invasive and noninvasive diagnostic tests. Using invasive tests, heterogeneous patterns of microvascular dysfunction, such as coronary<a href="https://solaci.org/en/2023/03/06/microvascular-dysfunction-in-symptomatic-patients-with-intermediate-coronary-lesions-prognostic-impact-according-to-different-patterns/" title="Read more" >...</a>

POKI: una nueva estrategia en bifurcaciones

Intracoronary Brachytherapy for Drug-Eluting Stent Restenosis

3 Year Clinical Outcome Analysis and Failure Predictors in the Use of Intracoronary Brachytherapy for Drug-Eluting Stent Restenosis In-stent restenosis (ISR) has been one of the greatest obstacles standing in the way of long term patency in percutaneous coronary interventions. However, the use of drug eluting stents (DES) and their development has helped reduce ISR<a href="https://solaci.org/en/2023/02/14/intracoronary-brachytherapy-for-drug-eluting-stent-restenosis/" title="Read more" >...</a>

Fentanilo en la angioplatia: ¿Cuál es el precio de un mayor confort en el procedimiento?

Ticagrelor or Prasugrel Post-PCI in Daily Practice Patients

The ISAR-REACT 5 showed a significant reduction in the composite outcome of death, acute myocardial infarction (AMI), or stroke when using prasugrel vs. ticagrelor in patients with acute coronary syndrome (ACS), mainly at the expense of an AMI reduction. While this study changed clinical practice, it has stirred some criticism regarding certain methodological aspects, such<a href="https://solaci.org/en/2022/12/19/ticagrelor-or-prasugrel-post-pci-in-daily-practice-patients/" title="Read more" >...</a>

Carotídeas asintomáticas ¿Tenemos todas las respuestas?

Is iFR Reliable After 5 Years? Analyzing the iFR-SWEDEHEART at 5 Years

Fractional flow reserve (FFR) proved to be very useful and safe in the FAME study, but its trade-off was using adenosine (which has a short half-life) and adverse reactions, which fortunately were rare. Subsequently, two large studies—the iFR-SWEDEHEART and DEFINE-FLAIR—demonstrated that instantaneous wave-free ratio (iFR) offered comparable results to FFR in the short term, avoiding<a href="https://solaci.org/en/2022/04/19/is-ifr-reliable-after-5-years-analyzing-the-ifr-swedeheart-at-5-years/" title="Read more" >...</a>

El uso de imágenes intravasculares para guiar la angioplastia reduce el riesgo de muerte cardiovascular en comparación con la angiografía

5-year TVF and MACCE in patients with deferred of revascularization after FFR: Is FFR enough?

Fractional flow reserve (FFR) has been shown effective and safe by different studies, yet not at 5 years.  The aim of this multicenter registry was to assess the impact of thrombotic risk (as per CREDO-Kyoto score) as a predictor of cardiovascular events at 5 years in patients with deferred revascularization after FFR measurement.  The score<a href="https://solaci.org/en/2022/04/13/5-year-tvf-and-macce-in-patients-with-deferred-of-revascularization-after-ffr-is-ffr-enough/" title="Read more" >...</a>

La FDA aprueba el ticagrelor en pacientes de alto riesgo como prevención primaria

Abbreviated DAPT in ACS: The End of Clopidogrel Monotherapy?

Compared with patients with chronic coronary syndromes, patients with acute coronary syndromes (ACS) are more likely to suffer from long term major adverse cardiac events (MACE). To prevent this, both the American and the European guidelines recommend prolonging dual antiplatelet therapy (DAPT) in this population for at least 12 months. However, in patients with certain clinical<a href="https://solaci.org/en/2022/03/21/abbreviated-dapt-in-acs-the-end-of-clopidogrel-monotherapy/" title="Read more" >...</a>

Access all contents of the 11th ProEducar Fellows Course

During the virtual SOLACI-CACI 2021 Congress, the 11th ProEducar Fellows Course—SOLACI’s traditional activity aimed at expanding knowledge and providing didactic tools for all interventional trainees in Latin America—was held. The course was a huge success: almost 1500 people accessed the Andreas Gruentzig Virtual Room where the activity took place. Furthermore, over 35 prestigious speakers from all<a href="https://solaci.org/en/2021/09/15/access-all-contents-of-the-11th-proeducar-fellows-course/" title="Read more" >...</a>

ESC 2021 | RIPCORD-2: Routine FFR Evaluation of All Epicardial Vessels During Angiography

The predecessor of this research—RIPCORD, published in 2014—showed that using fractional flow reserve (FFR) changes the treatment strategy in about 25% of patients. That marked the rise of FFR. In fact, the DEFER, FAME, and FAME 2 studies offered results consistent with the original RIPCORD. In this research, authors tested the hypothesis of systematic use of<a href="https://solaci.org/en/2021/09/01/esc-2021-ripcord-2-routine-ffr-evaluation-of-all-epicardial-vessels-during-angiography/" title="Read more" >...</a>

ACC 2021 | HOST-EXAM: Clopidogrel vs AAS como monoterapia post DAPT en las angioplastias

ACC 2021 | HOST-EXAM: Clopidogrel vs ASA monotherapy post DAPT in PCI patients

Clopidogrel monotherapy after dual antiplatelet therapy (DAPT) was associated with reduced mortality, MI, stroke, and other events in patients receiving PCI compared against aspirin monotherapy (ASA). This information was provided by the Korean HOST-EXAM study, presented at ACC 2021 scientific sessions, and simultaneously published in the Lancet. Researchers followed patients for 2 years and observed<a href="https://solaci.org/en/2021/05/20/acc-2021-host-exam-clopidogrel-vs-asa-monotherapy-post-dapt-in-pci-patients/" title="Read more" >...</a>

¿Son los stents con polímero bioabsorbible más trombogénicos que los de segunda generación con polímero durable?

ISAR-TEST-5: 10 años de los DES con polímero vs sin polímero

After 10 years, unstable or chronic coronary patients revascularized with drug-eluting stents (DES) had similar, very good outcomes regardless of whether the DES did or did not have a polymer, according to the ISAR-TEST-5 study, recently published in J Am Coll Cardiol. The 10-year device-oriented endpoints occurred in 43.8% of patients treated with a polymer-free sirolimus-eluting<a href="https://solaci.org/en/2020/07/30/isar-test-5-10-anos-de-los-des-con-polimero-vs-sin-polimero-2/" title="Read more" >...</a>

chronic stable angina